Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00046501 · ClinicalTrials.gov registry record · Phase 3
Compare Blood Sugar Level Between Lantus in the Morning and Other Insulins in Type 1 Diabetes Adolescents
A Phase 3 study of Diabetes Mellitus, sponsored by Sanofi.
- Completed
- Registry status
- Phase 3
- Development phase
- 250
- Enrollment target
- 1
- Study location
NCT00046501: Completed Phase 3 study of Diabetes Mellitus, sponsored by Sanofi.
NCT00046501 is a Phase 3 study of Diabetes Mellitus that has completed, run by Sanofi. The registered enrollment target is 250 participants, below the 1,866-participant average among 208 other Diabetes Mellitus trials with a reported enrollment target (87% lower). The trial reports 1 study location across 1 state. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT00046501, a Phase 3 study of Diabetes Mellitus, has completed, sponsored by Sanofi.
- COMPLETED
- Registry status
- Phase 3
- Development phase
- 250 participants
- Enrollment target
- 1
- Study location
Study Summary
The purpose of the study is to compare the effect in blood sugar control between Lantus and twice daily intermediate acting insulins (NPH or Lente) when used as the basal insulin in a multiple daily injection setting with fast acting insulin (Lispro)
Conditions Studied
Interventions
- DRUG Lispro
- DRUG Lantus (insulin glargine [rDNA origin] injection)
- DRUG Humulin N
- DRUG Humulin L
Study Locations (1)
New Jersey
- Aventis - Bridgewater
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 250 participants |
| Start Date | 2002-11 |
| Phase | Phase 3 |
What the finished NCT00046501 record still lists
NCT00046501 is an interventional study that assigns participants to a tested intervention. The registered 250 participants enrollment target is mid-sized for trials with a published cap, below the 1,866-participant average among 208 other Diabetes Mellitus trials with a reported enrollment target (87% lower).
The record links to 1 condition, with Diabetes Mellitus appearing as the primary indexed condition, and to 4 interventions - of which Lispro is the first listed.
NCT00046501 reports a single indexed study location in New Jersey.
Frequently Asked Questions
What is clinical trial NCT00046501 about?
NCT00046501 is a clinical study titled "Compare Blood Sugar Level Between Lantus in the Morning and Other Insulins in Type 1 Diabetes Adolescents". The purpose of the study is to compare the effect in blood sugar control between Lantus and twice daily intermediate acting insulins (NPH or Lente) when used as the basal insulin in a multiple daily injection setting with fast acting insulin (Lispro)
What is the current status of trial NCT00046501?
This trial is currently completed. It is a Phase 3 study. The enrollment target is 250 participants. The study started on 2002-11.
What conditions does trial NCT00046501 study?
This clinical trial studies the following conditions: Diabetes Mellitus.
What interventions are being tested in trial NCT00046501?
The interventions under investigation include: Lispro (DRUG), Lantus (insulin glargine [rDNA origin] injection) (DRUG), Humulin N (DRUG), Humulin L (DRUG).
Who is sponsoring clinical trial NCT00046501?
This trial is sponsored by Sanofi, which has 713 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT00046501 being conducted?
This trial has 1 study location across New Jersey. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Diabetes Mellitus
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
Where NCT00046501's enrollment target sits among peer trials
250 79th of 208 higher than 129 of 208 other Diabetes Mellitus trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Diabetes Mellitus trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
-
A Study to Evaluate ENERGI-F703 GEL in Diabetic Foot Ulcer
RECRUITING · Phase 3
-
Dapagliflozin in Patients With Atrial Fibrillation (DAPA-AF)
RECRUITING · Phase 3
-
Effect of a Decision Aid About Statin Use in Patients With Type 2 Diabetes Mellitus
COMPLETED · Phase 3
-
Treatment of Peripheral Neuropathy in Patients With Diabetes
COMPLETED · Phase 3
-
Action to Control Cardiovascular Risk in Diabetes (ACCORD)
COMPLETED · Phase 3
-
Efficacy of Alogliptin and Pioglitazone in Subjects With Type 2 Diabetes Mellitus
COMPLETED · Phase 3
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT00483249 · 250 participants · NA
Endovascular Exclusion of Thoracoabdominal and/or Paravisceral Abdominal Aortic Aneurysm
- NCT00777712 · 250 participants
Mechanisms Underlying Impaired Diabetic Wound Healing
- NCT01451502 · 250 participants · NA
Infusion of Cell Populations From Unlicensed Umbilical Cord Blood Units
- NCT01771718 · 250 participants
Pilot Study on In-vivo Non-invasive Skin Imaging Using Multiphoton Microscopy
Similar registry start date
- NCT05988463 · started 2027-01-01 · Phase 1
Dose-Escalation Study of Artesunate Patients With IPF
- NCT07219706 · started 2026-12-10 · NA
Dietary Fiber and Time Restricted Eating
- NCT02831335 · started 2026-12-01
Technical Development of Multi-Parametric Renocerebral MRI
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia